CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $183.02M, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -1.36: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
183.02MUSDvs all stocks (USD)
Revenue (TTM)
14.48MUSDvs all stocks (USD)
Profit Margin
-180.30%vs Biotechnology peers
Beta
0.1500xvs all stocks
52-Week Change
-25.41%vs all stocks
Market Capitalization
183.02MUSDvs all stocks (USD)
Enterprise Value
142.04MUSDvs all stocks (USD)
Forward P/E
-6.40xvs Biotechnology peers
Price to Sales (TTM)
12.60xvs Biotechnology peers
Price to Book (MRQ)
4.41xvs Biotechnology peers
Enterprise to Revenue
9.81xvs Biotechnology peers
Enterprise to EBITDA
-5.26xvs Biotechnology peers
Gross Margin
21.90%vs Biotechnology peers
Profit Margin
-180.30%vs Biotechnology peers
Operating Margin
-541.02%vs Biotechnology peers
Return on Assets (TTM)
-23.51%vs Biotechnology peers
Return on Equity (TTM)
-71.82%vs Biotechnology peers
Revenue (TTM)
14.48MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.22USDUpdated Jul 9, 2026Quarterly Revenue Growth
-62.70%vs Biotechnology peers
Gross Profit (TTM)
2.84MUSDvs all stocks (USD)
EBITDA (TTM)
-27.02MUSDvs all stocks (USD)
Net Income (TTM)
-26.11MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-18.77MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-18.44MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 9, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
16.96MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
13.71MUSDFY2025 · Dec 31, 2025Gross Profit
3.25MUSDFY2025 · Dec 31, 2025Operating Income
-25.28MUSDvs all stocks (USD)
Pre-tax Income
-23.71MUSDFY2025 · Dec 31, 2025Income Tax Expense
169.00KUSDFY2025 · Dec 31, 2025Net Income
-23.88MUSDFY2025 · Dec 31, 2025EBIT
-23.33MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-22.21MUSDFY2025 · Dec 31, 2025Research & Development
14.32MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
13.93MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.86MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
380.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.10USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.10USDFY2025 · Dec 31, 2025Basic Shares Outstanding
11.38MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
11.38MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-23.88MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-12.85MUSDFY2025 · Dec 31, 2025Free Cash Flow
-18.35MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
4.80MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-23.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.86MUSDFY2025 · Dec 31, 2025Stock-based Compensation
3.11MUSDFY2025 · Dec 31, 2025Other Non-cash Items
201.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
4.88MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.35MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.36MUSDFY2025 · Dec 31, 2025Capital Expenditures
-5.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-5.50MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.43MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
25.99MUSDFY2025 · Dec 31, 2025Shares Outstanding
12.85MSharesUpdated Jul 9, 2026Float Shares
8.91MSharesUpdated Jul 9, 2026Shares Short
1.63MSharesUpdated Jul 9, 2026Short Ratio
17.68daysvs all stocks
Short % of Shares Outstanding
14.47%vs all stocks
% Held by Insiders
15.86%vs all stocks
% Held by Institutions
58.22%vs all stocks
Total Cash (MRQ)
44.65MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.47USDUpdated Jul 9, 2026Total Debt (MRQ)
8.13MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1962xvs Biotechnology peers
Current Ratio (MRQ)
2.41xvs Biotechnology peers
Book Value per Share (MRQ)
3.22USDUpdated Jul 9, 2026Total Assets
86.25MUSDvs all stocks (USD)
Total Current Assets
59.96MUSDFY2025 · Dec 31, 2025Total Liabilities
42.62MUSDFY2025 · Dec 31, 2025Total Non-current Assets
26.29MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
16.91MUSDFY2025 · Dec 31, 2025Total Current Liabilities
25.71MUSDFY2025 · Dec 31, 2025Cash
4.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
4.80MUSDFY2025 · Dec 31, 2025Other Short-term Investments
48.34MUSDFY2025 · Dec 31, 2025Accounts Receivable
1.62MUSDFY2025 · Dec 31, 2025Inventory
4.09MUSDFY2025 · Dec 31, 2025Accounts Payable
3.61MUSDFY2025 · Dec 31, 2025Deferred Revenue
1.18MUSDFY2025 · Dec 31, 2025Other Current Liabilities
13.53MUSDFY2025 · Dec 31, 2025Long-term Debt
8.15MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
8.29MUSDFY2025 · Dec 31, 2025Common Stock (Book)
258.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-228.93MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
43.63MUSDvs all stocks (USD)
52-Week Low
13.54USDUpdated Jul 9, 202652-Week High
21.25USDUpdated Jul 9, 202652-Week Change
-25.41%vs all stocks
Beta
0.1500xvs all stocks
50-Day MA
16.02USDUpdated Jul 9, 2026200-Day MA
17.32USDUpdated Jul 9, 2026Avg 10-Day Volume
80.42KSharesUpdated Jul 9, 2026Avg 30-Day Volume
99.65KSharesUpdated Jul 9, 2026Diluted EPS (TTM)
-2.26USDUpdated Jul 9, 2026Other Income / Expense
753.00KUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.41Altman Z-Score: -1.36
Financial Health
Altman Z-Score -1.36: distress zoneCritical
Altman Z-Score: -1.36
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $183.02M, lower than 95% of all stocks globallySignificant
Market cap (USD): 183,016,111Global P5: 269,387,740.27
Revenue is $14.48M, lower than 95% of all stocks globallySignificant
Revenue (USD): 14,479,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Cabio Biotech Wuhan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
NervGen Pharma Corp.
Tier 1ProductionApproval-Gated PipelineRule
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Rightongene Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonix Pharmaceuticals Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Voyager Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ADC Therapeutics S.A.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Beam Therapeutics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC